Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 164,11
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 164,09
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 181,15
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 182,64
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: New.
Idioma: Inglés
Publicado por Springer Berlin Heidelberg, 2014
ISBN 10: 3642445802 ISBN 13: 9783642445804
Librería: moluna, Greven, Alemania
EUR 136,16
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 181,32
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 201,41
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. pp. 246.
Librería: preigu, Osnabrück, Alemania
EUR 140,00
Cantidad disponible: 5 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. Therapeutic Kinase Inhibitors | Ingo K. Mellinghoff (u. a.) | Taschenbuch | Current Topics in Microbiology and Immunology | x | Englisch | 2014 | Springer | EAN 9783642445804 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Idioma: Inglés
Publicado por Springer Berlin Heidelberg, 2014
ISBN 10: 3642445802 ISBN 13: 9783642445804
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 160,49
Cantidad disponible: 1 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as 'chemotherapy' and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Librería: Revaluation Books, Exeter, Reino Unido
EUR 232,58
Cantidad disponible: 2 disponibles
Añadir al carritoPaperback. Condición: Brand New. reprint edition. 234 pages. 8.75x6.00x0.50 inches. In Stock.
Librería: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 126,26
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: new. Questo è un articolo print on demand.
Idioma: Inglés
Publicado por Springer Berlin Heidelberg Apr 2014, 2014
ISBN 10: 3642445802 ISBN 13: 9783642445804
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
EUR 160,49
Cantidad disponible: 2 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as 'chemotherapy' and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert. 244 pp. Englisch.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 211,76
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand pp. 246 30 Illus. (21 Col.).
Idioma: Inglés
Publicado por Springer Berlin Heidelberg, Springer Berlin Heidelberg Apr 2014, 2014
ISBN 10: 3642445802 ISBN 13: 9783642445804
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
EUR 160,49
Cantidad disponible: 1 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as ¿chemotherapy¿ and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editorsinvited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authorshope these lessons will be instructive for the novice as well as the expert.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 244 pp. Englisch.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 213,13
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. PRINT ON DEMAND pp. 246.